[Transition experience of patients with neuromuscular disease]

Valeria Greif1, Florencia Ugo1,2, M Fernanda de Castro Pérez1

  • 1Hospital de Pediatría SAMIC "Prof. Dr. Juan P. Garrahan", Buenos Aires, Argentina.

Insights

This study details a clinical practice for transitioning adolescents with neuromuscular diseases from pediatric to adult care. It highlights achievements and challenges in managing these chronic genetic disorders.

Area of Science:

  • Neurology
  • Pediatrics
  • Healthcare Management

Background:

  • Neuromuscular diseases are chronic, progressive genetic disorders often leading to physical and emotional disabilities.
  • Increased survival rates in pediatric patients necessitate a transition to adult healthcare settings.
  • This transition presents significant challenges for patients and healthcare systems.

Purpose of the Study:

  • To report on a clinical practice designed for the transition of adolescents with neuromuscular diseases.
  • To evaluate the achievements, findings, and challenges of this transition process.
  • To inform future strategies for pediatric to adult care transitions in chronic diseases.

Main Methods:

  • A collaborative clinical practice was established between Hospital Garrahan and Hospital Ramos Mejía.
  • The program focused on the transition of 27 adolescents with neuromuscular diseases during 2015.
  • The process involved assessing and addressing the unique needs of this patient population.

Main Results:

  • The experience provided valuable insights into the practical aspects of transitioning care.
  • Specific achievements and challenges encountered during the transition were documented.
  • Data gathered informs the refinement of transition protocols for neuromuscular disease patients.

Conclusions:

  • Successful transition of care requires careful planning and inter-institutional collaboration.
  • Addressing both medical and psychosocial needs is crucial for adolescents with neuromuscular diseases.
  • This clinical practice offers a model for managing the complexities of lifelong care for chronic conditions.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.1K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
The Neuromuscular Junction01:19

The Neuromuscular Junction

The nervous system consists of complex motor neuron circuits, including upper motor neurons originating from the cerebral cortex and lower motor neurons starting in the spinal cord, coordinating both voluntary and involuntary movements. Among these, somatic motor neurons activate skeletal muscles and are classified into alpha, beta, and gamma types. Alpha neurons are vital for voluntary movement coordination, while gamma neurons adjust muscle spindle sensitivity, and the function of beta...
21.0K
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.5K